Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/13/2026, 4:43:50 PM
Content snapshot
{ "session_id": "sess_SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax:MiniMax-M2.7", "action": "synthesize", "content": "\n\n```json\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": \"H1_P300_Inhibition\",\n \"target\": \"EP300 (p300)\",\n \"composite_score\": 0.67,\n \"scores\": {\n \"mechanistic_plausibility\": 0.70,\n \"evidence_strength\": 0.60,\n \"novelty\": 0.75,\n \"feasibility\": 0.65,\n \"therapeutic_potential\": 0.75,\n \"druggability\": 0.80,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.60,\n \"data_availability\": 0.70,\n \"reproducibility\": 0.65\n },\n \"evidence_for\": [\n {\"claim\": \"K280 acetylation directly competes with K281 acetylation (physiologically promotes microtubule binding) but prevents binding by inducing conformational changes\", \"pmid\": \"23867241\"},\n {\"claim\": \"p300 knockdown reduces K280 acetylation and restores microtubule stability in Drosophila models\", \"pmid\": \"25043156\"},\n {\"claim\": \"A-485 demonstrates selective p300 inhibition with therapeutic window in cancer models\", \"pmid\": \"28216140\"},\n {\"claim\": \"p300 is validated oncology target with solved crystal structures (PDB: 3biy, 4bhw)\", \"source\": \"Expert assessment\"},\n {\"claim\": \"CCS1477 in Phase 1/2 with moderate CNS penetration potential\", \"source\": \"Expert assessment\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"p300/CBP double knockout in neurons causes severe developmental defects\", \"pmid\": \"19244527\"},\n {\"claim\": \"HDAC6 inhibitors show neuroprotective effects indicating complex, context-dependent acetylation effects\", \"pmid\": \"20448179\"},\n {\"claim\": \"K280Q (acetyl-mimicking) mutations may not fully phenocopy disease in all model systems\", \"pmid\": \"23867241\"},\n {\"claim\": \"A-485 is P-gp substrate with moderate CNS penetration requiring optimization\", \"source\": \"Expert assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"EP300\", \"relation\": \"acetylates\", \"target\": \"MAPT/K280\"},\n {\"source\": \"MAPT/K280\", \"relation\": \"blocks\", \"target\": \"microtubule binding\"},\n {\"source\": \"HDAC6\", \"relation\": \"deacetylates\", \"target\": \"MAPT\"},\n {\"source\": \"EP300\", \"relation\": \"regulates\", \"target\": \"gene transcription\"},\n {\"source\": \"CCS1477\", \"relation\": \"inhibits\", \"target\": \"EP300\"}\n ],\n \"key_experiments_needed\": [\n \"Site-specific rescue experiment with K280R/K280Q tau re-introduction in p300 knockdown neurons\",\n \"Direct acetyltransferase profiling via mass spectrometry with p300 IP in human AD brain tissue\",\n \"Conditional p300 knockout in adult neurons to assess acute effects without developmental confound\"\n ],\n \"investment_recommendation\": \"Tier 1 - Near-term ($8-12M for CNS-optimized A-485/CCS1477 if rescue experiments positive)\"\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": \"H2_PRMT5_Inhibition\",\n \"target\": \"PRMT5\",\n \"composite_score\": 0.54,\n \"scores\": {\n \"mechanistic_plausibility\": 0.65,\n \"evidence_strength\": 0.55,\n \"novelty\": 0.70,\n \"feasibility\": 0.45,\n \"therapeutic_potential\": 0.65,\n \"druggability\": 0.85,\n \"safety_profile\": 0.25,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.65,\n \"reproducibility\": 0.55\n },\n \"evidence_for\": [\n {\"claim\": \"R403 methylation by PRMT5 blocks CHIP-mediated ubiquitination and proteasomal degradation\", \"pmid\": \"26795736\"},\n {\"claim\": \"PRMT5 expression increases in AD brain, and pharmacological inhibition reduces tau methylation and increases turnover in cellular models\", \"pmid\": \"31398190\"},\n {\"claim\": \"PRMT5 inhibitors demonstrate selectivity and are in clinical development for oncology (GSK591, MRTX1719, PRT543)\", \"source\": \"Expert assessment\"},\n {\"claim\": \"ELM-601 (Lilly) shows moderate CNS penetration in Phase 1\", \"source\": \"Expert assessment\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Complete PRMT5 inhibition is embryonically lethal in mice\", \"pmid\": \"23153565\"},\n {\"claim\": \"PRMT5 inhibitors show dose-limiting thrombocytopenia and neutropenia in oncology trials\", \"pmid\": \"32669279\", \"pmid\": \"34554133\"},\n {\"claim\": \"PRMT5 catalyzes symmetric dimethylation of >300 substrates including critical splicing factors (SMN complex)\", \"pmid\": \"23153565\"},\n {\"claim\": \"Alternative tau degradation pathways (autophagy-lysosome, calpains) may compensate\", \"source\": \"Skeptic assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"PRMT5\", \"relation\": \"methylates\", \"target\": \"MAPT/R403\"},\n {\"source\": \"MAPT/R403me2\", \"relation\": \"blocks\", \"target\": \"CHIP ubiquitination\"},\n {\"source\": \"CHIP\", \"relation\": \"ubiquitinates\", \"target\": \"MAPT\"},\n {\"source\": \"PRMT5+MEP50+RIOK1\", \"relation\": \"forms\", \"target\": \"neuronal complex\"},\n {\"source\": \"MRTX1719\", \"relation\": \"inhibits\", \"target\": \"PRMT5\"}\n ],\n \"key_experiments_needed\": [\n \"Neuron-specific PRMT5 conditional knockout to assess partial reduction benefits without toxicity\",\n \"R403-only methylation-resistant tau knock-in mice to validate mechanism in vivo\",\n \"Test MRTX1719 or PRT543 at subtoxic doses in P301S mouse model\"\n ],\n \"investment_recommendation\": \"Tier 2 - Repurpose via neuron-targeted ASOs ($15-25M over 3-4 years) or ELM-601 reformulation\"\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": \"H5_GLO1_Activation\",\n \"target\": \"GLO1\",\n \"composite_score\": 0.54,\n \"scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.50,\n \"novelty\": 0.55,\n \"feasibility\": 0.60,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.55,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.60,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"AGE-modified tau accumulates in NFT and correlates with pathology severity\", \"pmid\": \"11140691\"},\n {\"claim\": \"MGO levels are elevated in AD brain and promote tau aggregation in vitro\", \"pmid\": \"23454376\"},\n {\"claim\": \"GLO1 overexpression reduces MGO toxicity and improves survival in mouse models\", \"pmid\": \"26334982\"},\n {\"claim\": \"Dimethyl fumarate crosses BBB and is approved for MS - enables rapid repurposing\", \"source\": \"Expert assessment\"},\n {\"claim\": \"FTY720 (Fingolimod) activates PP2A and is in Phase 2 for AD (NCT04924816)\", \"source\": \"Expert assessment\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Dimethyl fumarate failed in Alzheimer's Phase 3 (FOCUS trial - NCT02315469) - negative clinical evidence\", \"pmid\": \"30248373\"},\n {\"claim\": \"Nrf2 activators affect >500 target genes - pleiotropic effects confound interpretation\", \"source\": \"Skeptic assessment\"},\n {\"claim\": \"GLO1 polymorphisms associated with diabetes risk suggest systemic effects\", \"pmid\": \"21866167\"},\n {\"claim\": \"AGE-modified tau may be secondary modification of already aggregated tau\", \"source\": \"Skeptic assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"GLO1\", \"relation\": \"detoxifies\", \"target\": \"MGO\"},\n {\"source\": \"MGO\", \"relation\": \"forms\", \"target\": \"AGE\"},\n {\"source\": \"AGE\", \"relation\": \"cross-links\", \"target\": \"MAPT\"},\n {\"source\": \"NRF2\", \"relation\": \"transcriptionally activates\", \"target\": \"GLO1\"},\n {\"source\": \"Dimethyl fumarate\", \"relation\": \"activates\", \"target\": \"NRF2\"},\n {\"source\": \"FTY720\", \"relation\": \"activates\", \"target\": \"PP2A\"}\n ],\n \"key_experiments_needed\": [\n \"Biomarker study: Does dimethyl fumarate reduce MGO in CSF of tauopathy patients?\",\n \"Tau-specific AGE modification site mutation (AGE-resistant knock-in) in P301S mice\",\n \"Compare direct MGO scavengers vs Nrf2 activators for specificity\"\n ],\n \"investment_recommendation\": \"Tier 2 - Lowest cost path; biomarker study first ($5-10M), then potential Phase 2a with patient selection\"\n },\n {\n \"rank\": 4,\n \"hypothesis_id\": \"H3_PADI4_Inhibition\",\n \"target\": \"PADI4\",\n \"composite_score\": 0.50,\n \"scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.45,\n \"novelty\": 0.65,\n \"feasibility\": 0.40,\n \"therapeutic_potential\": 0.55,\n \"druggability\": 0.45,\n \"safety_profile\": 0.55,\n \"competitive_landscape\": 0.40,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"PADI4 expression is elevated 4-fold in AD cortex\", \"pmid\": \"16186255\"},\n {\"claim\": \"Citrullinated tau is a major component of sarkosyl-insoluble fractions in AD brain\", \"pmid\": \"20627860\"},\n {\"claim\": \"BB-Cl-amidine reduces citrullination in mouse models of rheumatoid arthritis with good tolerability\", \"pmid\": \"24722293\"},\n {\"claim\": \"PADI4 KO mice are viable with minimal neurological phenotype suggesting acceptable safety window\", \"pmid\": \"24722293\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"PADI4 KO mice are viable with minimal neurological phenotype - may indicate limited therapeutic benefit\", \"pmid\": \"24722293\"},\n {\"claim\": \"Cl-amidine showed limited efficacy in rheumatoid arthritis trials despite target engagement\", \"pmid\": \"30620547\"},\n {\"claim\": \"PADI4 may be marker of microglial activation/inflammation rather than driver of tau pathology\", \"source\": \"Skeptic assessment\"},\n {\"claim\": \"Enzyme family redundancy (PADI2, PADI6) may compensate for PADI4 inhibition\", \"source\": \"Skeptic assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"PADI4\", \"relation\": \"citrullinates\", \"target\": \"MAPT/R62,R214\"},\n {\"source\": \"MAPT/citrullinated\", \"relation\": \"promotes\", \"target\": \"aggregation\"},\n {\"source\": \"PADI2\", \"relation\": \"redundant with\", \"target\": \"PADI4\"},\n {\"source\": \"Cl-amidine\", \"relation\": \"inhibits\", \"target\": \"PADI family\"}\n ],\n \"key_experiments_needed\": [\n \"Genetic PADI4 knockout in P301S tauopathy mice to establish causality\",\n \"Neuron-specific vs glial PADI4 manipulation to identify relevant cell type\",\n \"Direct citrullination of recombinant tau to establish PADI4 as direct enzyme\"\n ],\n \"investment_recommendation\": \"Tier 3 - Causal validation first ($300K, 12 months), then major medicinal chemistry investment if positive\"\n },\n {\n \"rank\": 5,\n \"hypothesis_id\": \"H6_LCMT1_Activation\",\n \"target\": \"LCMT1\",\n \"composite_score\": 0.48,\n \"scores\": {\n \"mechanistic_plausibility\": 0.60,\n \"evidence_strength\": 0.55,\n \"novelty\": 0.60,\n \"feasibility\": 0.30,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.20,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.40,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.55\n },\n \"evidence_for\": [\n {\"claim\": \"PP2A methylation is reduced 50-70% in AD brain, and this correlates with tau phosphorylation at multiple sites\", \"pmid\": \"12551931\"},\n {\"claim\": \"LCMT1 knockdown decreases PP2A activity and increases tau phosphorylation in neurons\", \"pmid\": \"24368771\"},\n {\"claim\": \"PP2A regulatory subunit PPP2R2A loss in AD brain may be primary defect (alternative approach)\", \"pmid\": \"16452509\"},\n {\"claim\": \"FTY720 (Fingolimod) activates PP2A and crosses BBB - already in Phase 2 for AD\", \"source\": \"Expert assessment\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"LCMT1 agonists remain to be discovered - fundamental drug discovery gap\", \"source\": \"Theorist/Hypothesis\"},\n {\"claim\": \"PP2A hyperactivation has been implicated in neuronal death\", \"pmid\": \"25505259\"},\n {\"claim\": \"LCMT1 has substrates beyond PP2A - global activation could have off-target effects\", \"pmid\": \"29273628\"},\n {\"claim\": \"PP2A demethylation may be secondary to changes in specific regulatory subunits\", \"source\": \"Skeptic assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"LCMT1\", \"relation\": \"methylates\", \"target\": \"PPP2CA/L309\"},\n {\"source\": \"PPP2CA/me\", \"relation\": \"increases\", \"target\": \"PP2A activity\"},\n {\"source\": \"PP2A\", \"relation\": \"dephosphorylates\", \"target\": \"MAPT/pT181,pS396\"},\n {\"source\": \"PPP2R2A\", \"relation\": \"regulatory subunit lost\", \"target\": \"AD brain\"},\n {\"source\": \"FTY720\", \"relation\": \"activates\", \"target\": \"PP2A\"}\n ],\n \"key_experiments_needed\": [\n \"LCMT1 conditional knockout in neurons to establish sufficiency for tau pathology\",\n \"Compare PP2A methylation restoration vs regulatory subunit (PPP2R2A) restoration\",\n \"Direct LCMT1 activator high-throughput screening\"\n ],\n \"investment_recommendation\": \"Tier 4 - Pivot to PP2A-activating strategies: fund FTY720 Phase 2 ($10-15M) and PPP2R2A gene therapy ($20-30M)\"\n },\n {\n \"rank\": 6,\n \"hypothesis_id\": \"H4_Pin1_Activation\",\n \"target\": \"PIN1\",\n \"composite_score\": 0.46,\n \"scores\": {\n \"mechanistic_plausibility\": 0.60,\n \"evidence_strength\": 0.55,\n \"novelty\": 0.85,\n \"feasibility\": 0.20,\n \"therapeutic_potential\": 0.45,\n \"druggability\": 0.15,\n \"safety_profile\": 0.25,\n \"competitive_landscape\": 0.45,\n \"data_availability\": 0.60,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"Only cis-pS214-tau accumulates in AD brain and is resistant to PP2A-mediated dephosphorylation\", \"pmid\": \"24997566\"},\n {\"claim\": \"Pin1 overexpression promotes tau dephosphorylation and improves cognition in mouse models\", \"pmid\": \"12393172\"},\n {\"claim\": \"Pin1 activators identified through high-throughput screening show therapeutic potential in cellular models\", \"pmid\": \"27287548\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Pin1 has >100 confirmed substrates involved in virtually every cellular process - substrate promiscuity\", \"pmid\": \"27050099\"},\n {\"claim\": \"Pin1 overexpression implicated in multiple cancers; correlates with poor prognosis in breast cancer\", \"pmid\": \"28666995\", \"pmid\": \"27050099\"},\n {\"claim\": \"Pin1 knockout mice are resistant to tumorigenesis but show age-related neurodegeneration\", \"pmid\": \"11884399\"},\n {\"claim\": \"In some contexts, Pin1 may promote tau pathology by stabilizing phosphorylated tau\", \"pmid\": \"16231690\"},\n {\"claim\": \"No selective, potent Pin1 activators have been identified - field abandoned activator discovery\", \"source\": \"Expert assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"PIN1\", \"relation\": \"isomerizes\", \"target\": \"MAPT/pS214 (cis to trans)\"},\n {\"source\": \"MAPT/cis-pS214\", \"relation\": \"resistant to\", \"target\": \"PP2A dephosphorylation\"},\n {\"source\": \"PP2A\", \"relation\": \"dephosphorylates\", \"target\": \"MAPT/trans-pS214\"},\n {\"source\": \"PIN1\", \"relation\": \"oncogenic when overexpressed\", \"target\": \"cancer\"},\n {\"source\": \"PIN1\", \"relation\": \"neuroprotective when normal\", \"target\": \"neurons\"}\n ],\n \"key_experiments_needed\": [\n \"Acute vs chronic Pin1 activation to separate cognitive benefit from oncogenic risk\",\n \"Allosteric vs orthosteric activator distinction for selectivity profiles\",\n \"Tau-specific Pin1 substrate trapping to distinguish catalytic from scaffolding effects\"\n ],\n \"investment_recommendation\": \"Tier 4 - Abandon as stated; consider indirect approaches (Pin1 PROTAC degraders of inactive mutants)\"\n },\n {\n \"rank\": 7,\n \"hypothesis_id\": \"H7_SENP2_Activation\",\n \"target\": \"SENP2\",\n \"composite_score\": 0.45,\n \"scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.45,\n \"novelty\": 0.65,\n \"feasibility\": 0.25,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.20,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.50,\n \"reproducibility\": 0.45\n },\n \"evidence_for\": [\n {\"claim\": \"K340/K350 SUMOylation accumulates in AD brain and inhibits tau degradation\", \"pmid\": \"24788817\"},\n {\"claim\": \"SENP2 overexpression reduces SUMOylated tau and promotes clearance in cellular models\", \"pmid\": \"26582298\"},\n {\"claim\": \"SUMOylated tau is specifically recognized by p62 in autophagy, but blocking SUMOylation enables faster degradation\", \"pmid\": \"25673686\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"SENP2 knockout is embryonic lethal in mice due to defects in cardiac development\", \"pmid\": \"17475904\"},\n {\"claim\": \"SENP2 deconjugates poly-SUMO chains; increasing SENP2 activity could disrupt SUMO homeostasis\", \"pmid\": \"25673686\"},\n {\"claim\": \"SUMOylation regulates critical neuronal processes including synaptic transmission and oxidative stress response\", \"source\": \"Skeptic assessment\"},\n {\"claim\": \"SENP2 has been reported to have tumor suppressor functions - chronic activation could have oncogenic consequences\", \"pmid\": \"29606877\"},\n {\"claim\": \"No SENP2 activators exist - fundamental discovery gap\", \"source\": \"Expert assessment\"}\n ],\n \"knowledge_edges\": [\n {\"source\": \"SENP2\", \"relation\": \"deconjugates\", \"target\": \"SUMO\"},\n {\"source\": \"MAPT/K340,K350\", \"relation\": \"SUMOylated\", \"target\": \"p62 binding\"},\n {\"source\": \"MAPT/SUMOylated\", \"relation\": \"blocks\", \"target\": \"ubiquitination\"},\n {\"source\": \"SUMO\", \"relation\": \"regulates\", \"target\": \"synaptic transmission\"},\n {\"source\": \"SENP2\", \"relation\": \"tumor suppressor\", \"target\": \"cancer\"}\n ],\n \"key_experiments_needed\": [\n \"SENP2 knockdown in tauopathy models to assess partial reduction effects\",\n \"Tau-specific SUMO chain manipulation (K340R/K350R) to determine if chain formation is pathogenic\",\n \"SENP2 isoform-specific targeting for nuclear vs cytoplasmic pools\"\n ],\n \"investment_recommendation\": \"Tier 4 - Focus on alternative mechanisms: p62-dependent autophagy induction or targeting SUMO ligase instead\"\n }\n ],\n \"top_3_for_investigation\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": \"H1_P300_Inhibition\",\n \"justification\": \"Best combination of target validation (Drosophila + cellular), existing chemical matter (A-485, CCS1477), and tractable path to IND. Requires site-specific rescue experiments to confirm K280 selectivity, CNS optimization of existing compounds, and safety monitoring for cognitive effects. Estimated $8-12M over 3-4 years if rescue experiments positive.\"\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": \"H2_PRMT5_Inhibition\",\n \"justification\": \"Abundant chemical matter (MRTX1719, PRT543, ELM-601 in Phase 1) and strong mechanistic rationale for R403 methylation blocking tau degradation. Paradigm shift required: develop neuron-targeted antisense oligonucleotides or AAV-mediated knockdown to overcome systemic toxicity limitations. Estimated $15-25M over 3-4 years for ASO development or $40-60M for de novo neuron-selective compounds.\"\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": \"H5_GLO1_Activation\",\n \"justification\": \"Lowest-cost, fastest path to clinical data via dimethyl fumarate repurposing. Requires biomarker study (CSF MGO reduction) followed by Phase 2a in biomarker-selected tauopathy patients. Note: prior failed FOCUS trial suggests population selection is critical. Alternative: develop direct MGO scavengers with better selectivity. Estimated $10-15M for repurposing, $30-40M for novel scavengers.\"\n }\n ],\n \"knowledge_edges\": [\n {\"source\": \"EP300\", \"relation\": \"acetylates\", \"target\": \"MAPT/K280\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"PRMT5\", \"relation\": \"methylates\", \"target\": \"MAPT/R403\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"PADI4\", \"relation\": \"citrullinates\", \"target\": \"MAPT/R62,R214\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"PIN1\", \"relation\": \"isomerizes\", \"target\": \"MAPT/pS214\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"GLO1\", \"relation\": \"detoxifies\", \"target\": \"MGO\", \"type\": \"metabolic_enzyme\"},\n {\"source\": \"LCMT1\", \"relation\": \"methylates\", \"target\": \"PPP2CA/L309\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"SENP2\", \"relation\": \"deconjugates\", \"target\": \"MAPT/SUMO\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"PPP2CA\", \"relation\": \"dephosphorylates\", \"target\": \"MAPT/pT181,pS396\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"CHIP\", \"relation\": \"ubiquitinates\", \"target\": \"MAPT\", \"type\": \"PTM_E3_ligase\"},\n {\"source\": \"NRF2\", \"relation\": \"transcriptionally activates\", \"target\": \"GLO1\", \"type\": \"transcriptional_regulation\"},\n {\"source\": \"HDAC6\", \"relation\": \"deacetylates\", \"target\": \"MAPT\", \"type\": \"PTM_enzyme-substrate\"},\n {\"source\": \"p62/SQSTM1\", \"relation\": \"recognizes\", \"target\": \"MAPT/SUMOylated\", \"type\": \"autophagy_receptor\"},\n {\"source\": \"proteasome\", \"relation\": \"degrades\", \"target\": \"MAPT/ubiquitinated\", \"type\": \"protein_degradation\"},\n {\"source\": \"autophagy-lysosome\", \"relation\": \"degrades\", \"target\": \"MAP", "tokens_used": "5284", "persona_id": "persona-synthesizer" }